AURKA Increase the Chemosensitivity of Colon Cancer Cells to Oxaliplatin by Inhibiting the TP53-Mediated DNA Damage Response Genes.

This study provided a possibility to use AURKA as a biomarker to predict the chemosensitivity of colon cancer to platinum in the clinic.
PMID: 32851091 [PubMed - in process]

Source: Biomed Res - August 29, 2020 Category: Research Authors: Shan B, Zhao R, Zhou J, Zhang M, Qi X, Wang T, Gong J, Wu Y, Zhu Y, Yang W, Zhang Y, Wang G, Li X Tags: Biomed Res Int Source Type: research